Cartesian Therapeutics

📍 Frederick, United States🗓 Founded 2016👥 67 employees💰 Last funded Jul 2016
Biotechnology Research
LinkedIn
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Cartesian Therapeutics?
Cartesian Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Cartesian Therapeutics last raise funding?
The most recent investment in Cartesian Therapeutics recorded on gritt.io was in July 2016.
When was Cartesian Therapeutics founded?
Cartesian Therapeutics was founded in 2016.
What industry is Cartesian Therapeutics in?
Cartesian Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Cartesian Therapeutics based?
Cartesian Therapeutics is headquartered in Frederick, United States.